 Meenakshi Jolly
Concepts (285)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lupus Erythematosus, Systemic | 74 | 2021 | 190 | 24.330 |
Why?
| | Quality of Life | 38 | 2021 | 636 | 8.450 |
Why?
| | Health Status | 11 | 2018 | 252 | 2.880 |
Why?
| | Severity of Illness Index | 28 | 2020 | 1233 | 2.730 |
Why?
| | Psychometrics | 15 | 2020 | 286 | 2.670 |
Why?
| | Rheumatology | 6 | 2019 | 80 | 2.320 |
Why?
| | Body Image | 6 | 2017 | 38 | 2.280 |
Why?
| | Adult | 54 | 2021 | 9760 | 2.080 |
Why?
| | Self Report | 7 | 2017 | 217 | 1.890 |
Why?
| | Female | 65 | 2021 | 18107 | 1.850 |
Why?
| | Middle Aged | 48 | 2021 | 11256 | 1.820 |
Why?
| | Humans | 83 | 2021 | 30741 | 1.730 |
Why?
| | Patient Outcome Assessment | 3 | 2015 | 49 | 1.660 |
Why?
| | Reproducibility of Results | 19 | 2020 | 875 | 1.660 |
Why?
| | Hydroxychloroquine | 3 | 2021 | 8 | 1.620 |
Why?
| | Lupus Erythematosus, Discoid | 3 | 2021 | 11 | 1.530 |
Why?
| | Cross-Cultural Comparison | 8 | 2020 | 40 | 1.510 |
Why?
| | Antirheumatic Agents | 3 | 2021 | 95 | 1.470 |
Why?
| | Male | 48 | 2021 | 17552 | 1.420 |
Why?
| | Pain | 7 | 2020 | 318 | 1.270 |
Why?
| | Cross-Sectional Studies | 14 | 2021 | 957 | 1.210 |
Why?
| | Fatigue | 4 | 2020 | 67 | 1.120 |
Why?
| | Lupus Erythematosus, Cutaneous | 2 | 2014 | 6 | 1.090 |
Why?
| | Health Status Indicators | 3 | 2014 | 82 | 1.050 |
Why?
| | Pneumococcal Infections | 1 | 2021 | 9 | 0.950 |
Why?
| | Interferon-alpha | 7 | 2014 | 82 | 0.930 |
Why?
| | Sickness Impact Profile | 4 | 2014 | 21 | 0.880 |
Why?
| | Antibodies, Antinuclear | 5 | 2018 | 21 | 0.870 |
Why?
| | Depression | 4 | 2020 | 502 | 0.870 |
Why?
| | Pain Measurement | 5 | 2019 | 475 | 0.850 |
Why?
| | Outpatient Clinics, Hospital | 1 | 2018 | 14 | 0.760 |
Why?
| | Lupus Nephritis | 2 | 2017 | 33 | 0.760 |
Why?
| | Delivery of Health Care, Integrated | 1 | 2018 | 30 | 0.740 |
Why?
| | Quality Indicators, Health Care | 1 | 2018 | 44 | 0.730 |
Why?
| | Academic Medical Centers | 1 | 2019 | 162 | 0.700 |
Why?
| | Cost of Illness | 2 | 2015 | 65 | 0.700 |
Why?
| | Factor Analysis, Statistical | 7 | 2020 | 75 | 0.690 |
Why?
| | Unnecessary Procedures | 1 | 2017 | 30 | 0.670 |
Why?
| | Physicians | 3 | 2015 | 112 | 0.660 |
Why?
| | Young Adult | 12 | 2020 | 2249 | 0.660 |
Why?
| | Culture | 2 | 2013 | 30 | 0.650 |
Why?
| | Tattooing | 2 | 2007 | 2 | 0.650 |
Why?
| | Canada | 4 | 2018 | 56 | 0.630 |
Why?
| | Biological Products | 1 | 2016 | 35 | 0.620 |
Why?
| | Adolescent | 11 | 2020 | 2627 | 0.610 |
Why?
| | Linear Models | 6 | 2018 | 277 | 0.580 |
Why?
| | Immunoglobulin lambda-Chains | 1 | 2014 | 4 | 0.560 |
Why?
| | Immunoglobulin kappa-Chains | 1 | 2014 | 5 | 0.560 |
Why?
| | Interleukin-10 | 1 | 2014 | 42 | 0.550 |
Why?
| | Language | 5 | 2020 | 78 | 0.540 |
Why?
| | Autoantibodies | 8 | 2013 | 116 | 0.540 |
Why?
| | Interleukin-6 | 1 | 2014 | 120 | 0.530 |
Why?
| | Arthritis, Rheumatoid | 4 | 2019 | 377 | 0.530 |
Why?
| | Posterior Leukoencephalopathy Syndrome | 1 | 2013 | 16 | 0.530 |
Why?
| | United States | 7 | 2018 | 2467 | 0.520 |
Why?
| | Teaching | 2 | 2019 | 62 | 0.520 |
Why?
| | Caregivers | 1 | 2015 | 147 | 0.510 |
Why?
| | Cultural Characteristics | 1 | 2013 | 25 | 0.510 |
Why?
| | Patient Education as Topic | 1 | 2014 | 192 | 0.510 |
Why?
| | Dermatology | 1 | 2012 | 8 | 0.500 |
Why?
| | Treatment Outcome | 10 | 2018 | 3850 | 0.500 |
Why?
| | Diagnostic Self Evaluation | 1 | 2012 | 16 | 0.500 |
Why?
| | Hospitals, County | 1 | 2012 | 4 | 0.500 |
Why?
| | Hospitals, University | 1 | 2012 | 45 | 0.490 |
Why?
| | Body Dysmorphic Disorders | 1 | 2011 | 4 | 0.480 |
Why?
| | Adaptation, Psychological | 5 | 2016 | 178 | 0.480 |
Why?
| | Longitudinal Studies | 6 | 2020 | 1432 | 0.470 |
Why?
| | Emotions | 3 | 2017 | 96 | 0.460 |
Why?
| | Immunoglobulin Light Chains | 1 | 2011 | 9 | 0.460 |
Why?
| | Polymorphism, Single Nucleotide | 8 | 2017 | 331 | 0.460 |
Why?
| | Quality of Health Care | 1 | 2012 | 135 | 0.440 |
Why?
| | Benchmarking | 1 | 2010 | 29 | 0.430 |
Why?
| | Demography | 1 | 2010 | 82 | 0.410 |
Why?
| | Income | 1 | 2010 | 71 | 0.400 |
Why?
| | Aged | 10 | 2021 | 10156 | 0.400 |
Why?
| | Genetic Predisposition to Disease | 6 | 2018 | 473 | 0.400 |
Why?
| | Activities of Daily Living | 2 | 2012 | 472 | 0.390 |
Why?
| | Clinical Trials as Topic | 4 | 2016 | 386 | 0.380 |
Why?
| | Case-Control Studies | 6 | 2014 | 694 | 0.360 |
Why?
| | Predictive Value of Tests | 4 | 2017 | 631 | 0.360 |
Why?
| | Randomized Controlled Trials as Topic | 3 | 2016 | 361 | 0.360 |
Why?
| | Stress, Psychological | 3 | 2020 | 278 | 0.360 |
Why?
| | Paracentesis | 1 | 2007 | 4 | 0.350 |
Why?
| | Vasculitis, Leukocytoclastic, Cutaneous | 1 | 2007 | 2 | 0.340 |
Why?
| | Suction | 1 | 2007 | 46 | 0.340 |
Why?
| | Genital Diseases, Female | 1 | 2006 | 11 | 0.330 |
Why?
| | Reference Values | 3 | 2014 | 258 | 0.330 |
Why?
| | Hyperuricemia | 1 | 2006 | 5 | 0.320 |
Why?
| | Chronic Disease | 2 | 2005 | 542 | 0.310 |
Why?
| | Takayasu Arteritis | 1 | 2005 | 1 | 0.310 |
Why?
| | Uveitis | 1 | 2005 | 8 | 0.310 |
Why?
| | Vasculitis | 1 | 2005 | 35 | 0.300 |
Why?
| | Chicago | 2 | 2018 | 945 | 0.290 |
Why?
| | Leukoencephalopathy, Progressive Multifocal | 1 | 2007 | 121 | 0.290 |
Why?
| | Pre-Eclampsia | 1 | 2004 | 8 | 0.290 |
Why?
| | Chlamydia trachomatis | 1 | 2004 | 16 | 0.280 |
Why?
| | Chlamydia Infections | 1 | 2004 | 8 | 0.280 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2005 | 228 | 0.280 |
Why?
| | Pregnancy Complications | 1 | 2004 | 57 | 0.280 |
Why?
| | African Americans | 6 | 2015 | 780 | 0.270 |
Why?
| | Prognosis | 3 | 2014 | 1045 | 0.270 |
Why?
| | Heart Diseases | 1 | 2005 | 102 | 0.270 |
Why?
| | Antibodies, Monoclonal | 1 | 2005 | 311 | 0.270 |
Why?
| | Translations | 2 | 2013 | 16 | 0.270 |
Why?
| | Depressive Disorder | 2 | 2018 | 213 | 0.260 |
Why?
| | Diagnosis, Differential | 3 | 2013 | 469 | 0.250 |
Why?
| | Comorbidity | 3 | 2013 | 562 | 0.240 |
Why?
| | Vaccination | 1 | 2021 | 42 | 0.230 |
Why?
| | Cardiovascular Diseases | 1 | 2006 | 391 | 0.230 |
Why?
| | Sex Factors | 2 | 2018 | 535 | 0.230 |
Why?
| | Immunocompromised Host | 1 | 2021 | 56 | 0.230 |
Why?
| | Prospective Studies | 3 | 2020 | 1891 | 0.220 |
Why?
| | Regression Analysis | 3 | 2020 | 323 | 0.210 |
Why?
| | Autoimmunity | 2 | 2010 | 23 | 0.210 |
Why?
| | Health Surveys | 2 | 2017 | 101 | 0.210 |
Why?
| | Azacitidine | 1 | 2019 | 13 | 0.200 |
Why?
| | Cohort Studies | 6 | 2017 | 1959 | 0.200 |
Why?
| | Multivariate Analysis | 2 | 2018 | 391 | 0.200 |
Why?
| | Databases, Factual | 1 | 2021 | 372 | 0.200 |
Why?
| | Asia | 1 | 2018 | 11 | 0.190 |
Why?
| | Appointments and Schedules | 1 | 2018 | 15 | 0.190 |
Why?
| | Europe | 1 | 2018 | 86 | 0.190 |
Why?
| | Faculty, Medical | 1 | 2019 | 30 | 0.190 |
Why?
| | Morbidity | 1 | 2018 | 71 | 0.190 |
Why?
| | Mentors | 1 | 2019 | 38 | 0.190 |
Why?
| | Patient Acuity | 1 | 2018 | 10 | 0.190 |
Why?
| | Sex Distribution | 1 | 2018 | 91 | 0.190 |
Why?
| | Age Factors | 3 | 2016 | 941 | 0.190 |
Why?
| | Enzyme Inhibitors | 1 | 2019 | 160 | 0.190 |
Why?
| | Workload | 1 | 2018 | 39 | 0.190 |
Why?
| | Phenotype | 4 | 2012 | 368 | 0.180 |
Why?
| | Arthritis, Experimental | 1 | 2019 | 139 | 0.180 |
Why?
| | Biomedical Research | 1 | 2019 | 85 | 0.180 |
Why?
| | Interferon Type I | 2 | 2017 | 20 | 0.180 |
Why?
| | Pilot Projects | 2 | 2020 | 440 | 0.180 |
Why?
| | DNA Methylation | 1 | 2019 | 165 | 0.170 |
Why?
| | Genome-Wide Association Study | 4 | 2012 | 308 | 0.170 |
Why?
| | Philippines | 2 | 2017 | 3 | 0.170 |
Why?
| | Blood Sedimentation | 1 | 2017 | 65 | 0.170 |
Why?
| | Psychiatric Status Rating Scales | 1 | 2018 | 386 | 0.170 |
Why?
| | Health Care Surveys | 1 | 2017 | 76 | 0.170 |
Why?
| | Risk Assessment | 2 | 2014 | 804 | 0.170 |
Why?
| | Toll-Like Receptors | 1 | 2017 | 29 | 0.170 |
Why?
| | Retrospective Studies | 2 | 2018 | 3456 | 0.170 |
Why?
| | Illinois | 1 | 2017 | 268 | 0.160 |
Why?
| | Health Status Disparities | 1 | 2017 | 68 | 0.160 |
Why?
| | France | 1 | 2016 | 39 | 0.160 |
Why?
| | Mental Health | 1 | 2017 | 114 | 0.160 |
Why?
| | Macrophages | 1 | 2017 | 114 | 0.160 |
Why?
| | Socioeconomic Factors | 3 | 2016 | 362 | 0.160 |
Why?
| | Arthralgia | 2 | 2008 | 119 | 0.150 |
Why?
| | Sleep Initiation and Maintenance Disorders | 1 | 2017 | 116 | 0.150 |
Why?
| | Hong Kong | 1 | 2015 | 3 | 0.150 |
Why?
| | Interferon Regulatory Factor-7 | 2 | 2017 | 4 | 0.150 |
Why?
| | Software | 1 | 2015 | 73 | 0.150 |
Why?
| | Self Concept | 2 | 2012 | 53 | 0.150 |
Why?
| | Cosmetic Techniques | 1 | 2014 | 4 | 0.150 |
Why?
| | Critical Pathways | 1 | 2014 | 23 | 0.140 |
Why?
| | Professional-Patient Relations | 1 | 2015 | 32 | 0.140 |
Why?
| | Magnetic Resonance Imaging | 2 | 2013 | 1244 | 0.140 |
Why?
| | Time Factors | 2 | 2017 | 1911 | 0.140 |
Why?
| | Focus Groups | 1 | 2014 | 91 | 0.140 |
Why?
| | Double-Blind Method | 1 | 2016 | 550 | 0.140 |
Why?
| | Chi-Square Distribution | 1 | 2014 | 181 | 0.140 |
Why?
| | Goals | 1 | 2014 | 49 | 0.140 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2015 | 527 | 0.140 |
Why?
| | Interferon Regulatory Factors | 1 | 2013 | 2 | 0.140 |
Why?
| | Turkey | 1 | 2013 | 5 | 0.130 |
Why?
| | Sleep | 1 | 2017 | 340 | 0.130 |
Why?
| | Genetic Variation | 2 | 2011 | 117 | 0.130 |
Why?
| | Promoter Regions, Genetic | 2 | 2011 | 106 | 0.130 |
Why?
| | Latin America | 1 | 2013 | 7 | 0.130 |
Why?
| | Combined Modality Therapy | 1 | 2014 | 473 | 0.130 |
Why?
| | Matched-Pair Analysis | 1 | 2012 | 24 | 0.120 |
Why?
| | Multiple Sclerosis | 1 | 2013 | 88 | 0.120 |
Why?
| | Self-Assessment | 1 | 2012 | 28 | 0.120 |
Why?
| | Feedback | 1 | 2012 | 26 | 0.120 |
Why?
| | Osteopontin | 1 | 2011 | 4 | 0.120 |
Why?
| | Ubiquitin-Conjugating Enzymes | 1 | 2011 | 6 | 0.120 |
Why?
| | Disease Management | 1 | 2013 | 149 | 0.120 |
Why?
| | DEAD-box RNA Helicases | 1 | 2011 | 5 | 0.120 |
Why?
| | Quality Improvement | 1 | 2013 | 169 | 0.120 |
Why?
| | Gene Expression Profiling | 1 | 2012 | 183 | 0.110 |
Why?
| | Complementary Therapies | 1 | 2011 | 15 | 0.110 |
Why?
| | Sensitivity and Specificity | 1 | 2013 | 594 | 0.110 |
Why?
| | DNA | 4 | 2013 | 140 | 0.110 |
Why?
| | Genetic Association Studies | 1 | 2011 | 90 | 0.110 |
Why?
| | Alleles | 4 | 2011 | 230 | 0.110 |
Why?
| | Class III Phosphatidylinositol 3-Kinases | 1 | 2010 | 1 | 0.110 |
Why?
| | Models, Genetic | 1 | 2010 | 44 | 0.110 |
Why?
| | Aged, 80 and over | 2 | 2019 | 5172 | 0.110 |
Why?
| | Epitopes | 1 | 2010 | 91 | 0.110 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2010 | 51 | 0.100 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2010 | 65 | 0.100 |
Why?
| | Self-Examination | 1 | 2009 | 3 | 0.100 |
Why?
| | Nuclear Proteins | 1 | 2010 | 96 | 0.100 |
Why?
| | Social Environment | 1 | 2010 | 93 | 0.100 |
Why?
| | California | 3 | 2017 | 34 | 0.100 |
Why?
| | Disease Models, Animal | 2 | 2019 | 831 | 0.100 |
Why?
| | Follow-Up Studies | 1 | 2014 | 2046 | 0.100 |
Why?
| | Educational Status | 1 | 2010 | 285 | 0.090 |
Why?
| | Cytokines | 1 | 2010 | 348 | 0.090 |
Why?
| | Analgesics, Non-Narcotic | 1 | 2008 | 18 | 0.090 |
Why?
| | Prevalence | 2 | 2011 | 546 | 0.090 |
Why?
| | Therapeutic Irrigation | 1 | 2007 | 66 | 0.080 |
Why?
| | Animals | 3 | 2019 | 5221 | 0.080 |
Why?
| | Fatal Outcome | 1 | 2007 | 76 | 0.080 |
Why?
| | Patient Satisfaction | 1 | 2010 | 308 | 0.080 |
Why?
| | Education, Medical, Undergraduate | 1 | 2007 | 36 | 0.080 |
Why?
| | Vulva | 1 | 2006 | 3 | 0.080 |
Why?
| | Injections, Intra-Articular | 1 | 2007 | 77 | 0.080 |
Why?
| | Data Collection | 1 | 2007 | 118 | 0.080 |
Why?
| | Joints | 1 | 2007 | 101 | 0.080 |
Why?
| | Skin Diseases | 1 | 2006 | 37 | 0.080 |
Why?
| | Cognition | 1 | 2014 | 1141 | 0.080 |
Why?
| | Hepatitis B | 1 | 2005 | 20 | 0.080 |
Why?
| | Probability | 1 | 2005 | 107 | 0.080 |
Why?
| | Disability Evaluation | 2 | 2020 | 330 | 0.080 |
Why?
| | Autoimmune Diseases | 2 | 2019 | 64 | 0.070 |
Why?
| | Pregnancy Outcome | 1 | 2004 | 20 | 0.070 |
Why?
| | Genotype | 3 | 2011 | 447 | 0.070 |
Why?
| | Sulfasalazine | 1 | 2004 | 4 | 0.070 |
Why?
| | Lactones | 1 | 2004 | 14 | 0.070 |
Why?
| | Sulfones | 1 | 2004 | 27 | 0.070 |
Why?
| | Doxycycline | 1 | 2004 | 23 | 0.070 |
Why?
| | Internship and Residency | 1 | 2007 | 187 | 0.070 |
Why?
| | Methotrexate | 1 | 2004 | 48 | 0.070 |
Why?
| | Myocardial Infarction | 1 | 2005 | 191 | 0.070 |
Why?
| | Drug Therapy, Combination | 1 | 2004 | 266 | 0.070 |
Why?
| | Synovial Fluid | 1 | 2004 | 137 | 0.070 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2004 | 109 | 0.070 |
Why?
| | Osteoarthritis, Knee | 1 | 2008 | 362 | 0.060 |
Why?
| | Pregnancy | 1 | 2004 | 452 | 0.060 |
Why?
| | Mice | 2 | 2019 | 1843 | 0.060 |
Why?
| | Hypertension | 1 | 2004 | 272 | 0.060 |
Why?
| | Ribonucleoproteins | 2 | 2011 | 4 | 0.060 |
Why?
| | Cell Line | 2 | 2012 | 354 | 0.060 |
Why?
| | Egypt | 1 | 2020 | 3 | 0.050 |
Why?
| | Anti-Bacterial Agents | 1 | 2004 | 403 | 0.050 |
Why?
| | Polymorphism, Genetic | 2 | 2011 | 96 | 0.050 |
Why?
| | Chromatin Immunoprecipitation | 1 | 2019 | 28 | 0.050 |
Why?
| | Gene Silencing | 1 | 2019 | 26 | 0.050 |
Why?
| | Anxiety | 1 | 2020 | 159 | 0.050 |
Why?
| | Flow Cytometry | 1 | 2019 | 224 | 0.050 |
Why?
| | B-Lymphocytes | 1 | 2019 | 95 | 0.050 |
Why?
| | Complement C1q | 1 | 2018 | 3 | 0.050 |
Why?
| | Malaria | 1 | 2018 | 5 | 0.050 |
Why?
| | Immunoglobulin M | 1 | 2018 | 22 | 0.050 |
Why?
| | Glucocorticoids | 1 | 2018 | 77 | 0.040 |
Why?
| | Immunoglobulin G | 1 | 2018 | 137 | 0.040 |
Why?
| | Georgia | 1 | 2017 | 16 | 0.040 |
Why?
| | Southeastern United States | 1 | 2017 | 15 | 0.040 |
Why?
| | Mice, Inbred MRL lpr | 1 | 2017 | 3 | 0.040 |
Why?
| | Interferon Regulatory Factor-3 | 1 | 2017 | 3 | 0.040 |
Why?
| | Japan | 1 | 2016 | 14 | 0.040 |
Why?
| | Australia | 1 | 2016 | 48 | 0.040 |
Why?
| | Social Class | 1 | 2017 | 72 | 0.040 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2017 | 72 | 0.040 |
Why?
| | Registries | 1 | 2017 | 203 | 0.040 |
Why?
| | Child | 1 | 2020 | 1547 | 0.040 |
Why?
| | Disabled Persons | 1 | 2016 | 110 | 0.040 |
Why?
| | Risk Factors | 2 | 2011 | 2611 | 0.030 |
Why?
| | 3' Untranslated Regions | 1 | 2011 | 4 | 0.030 |
Why?
| | Anemia, Hemolytic | 1 | 2011 | 3 | 0.030 |
Why?
| | Autoantigens | 1 | 2011 | 38 | 0.030 |
Why?
| | Thrombocytopenia | 1 | 2011 | 31 | 0.030 |
Why?
| | Mexican Americans | 1 | 2011 | 28 | 0.030 |
Why?
| | Receptors, Lysophosphatidic Acid | 1 | 2010 | 1 | 0.030 |
Why?
| | Databases, Genetic | 1 | 2010 | 12 | 0.030 |
Why?
| | Principal Component Analysis | 1 | 2010 | 27 | 0.030 |
Why?
| | Aminopeptidases | 1 | 2010 | 7 | 0.030 |
Why?
| | Protein Structure, Quaternary | 1 | 2010 | 8 | 0.030 |
Why?
| | Antibody Specificity | 1 | 2010 | 58 | 0.030 |
Why?
| | Immunoprecipitation | 1 | 2010 | 27 | 0.030 |
Why?
| | Immunoblotting | 1 | 2010 | 66 | 0.030 |
Why?
| | Transfection | 1 | 2010 | 153 | 0.030 |
Why?
| | Gene Frequency | 1 | 2010 | 86 | 0.030 |
Why?
| | Interferon-gamma | 1 | 2010 | 120 | 0.030 |
Why?
| | Genetic Loci | 1 | 2010 | 68 | 0.030 |
Why?
| | Polymerase Chain Reaction | 1 | 2010 | 209 | 0.030 |
Why?
| | DNA-Binding Proteins | 1 | 2010 | 258 | 0.020 |
Why?
| | Gene Expression Regulation | 1 | 2010 | 348 | 0.020 |
Why?
| | Signal Transduction | 1 | 2011 | 582 | 0.020 |
Why?
| | Algorithms | 1 | 2010 | 421 | 0.020 |
Why?
| | Knee Joint | 1 | 2008 | 743 | 0.010 |
Why?
|
|
Jolly's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|